Tanespimycin (** Generic (investigational) **)

Other Medications

EU Experimental ES med_spain_not_available 1 Clinical Trials

Description

Tanespimycin (also known as 17-N-allylamino-17-demethoxygeldanamycin or 17-AAG) is an investigational drug being studied in clinical trials. It is currently not approved for treating colorectal cancer or any other cancer. The main goal of the early clinical trials, like the one described (NCT00004065), was to determine the highest safe dose (maximum tolerated dose) of the drug in patients with advanced cancers that had stopped responding to standard treatments (refractory). These trials also looked at how the drug affects certain proteins within the cancer cells. Tanespimycin is given intravenously (IV) in cycles.

Mechanism of Action

Tanespimycin belongs to a class of drugs called geldanamycin derivatives. It works by targeting heat shock proteins (HSPs), specifically HSP90. HSP90 helps many other proteins, including some involved in cancer cell growth and survival, to fold correctly and stay active. By inhibiting HSP90, tanespimycin can disrupt the function of these proteins, potentially leading to cancer cell death or slowing their growth. The specific proteins affected and the overall impact on cancer are still being investigated in clinical trials.

Side Effects

Because tanespimycin is an investigational drug Its side effects are still being fully evaluated in ongoing clinical trials. The trial mentioned (NCT00004065) was a Phase 1 study focused on safety and determining the maximum tolerated dose. Common side effects observed in early trials with similar drugs or in this specific trial might include nausea Vomiting Fatigue Diarrhea And changes in liver function tests. More specific and comprehensive information about side effects will become available as more patients are treated in later-phase trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00004065 med_phase_prefix1
Archived
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
United States

Quick Info

Brand Name** Generic (investigational) **
CategoryOther Medications
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.